Cancer Patents (Class 514/19.3)
  • Patent number: 12121565
    Abstract: The present disclosure provides, in part, compositions and methods of increasing the efficacy of anti-PD-1/PD-L1 antibody immunotherapy in a subject. The compositions and methods comprise an NLRP3 inhibitor used in combination with a PD-1 or PD-L1 inhibitor for the treatment of cancer.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: October 22, 2024
    Assignee: Duke University
    Inventors: Brent Hanks, Balamayooran Theivanthiran
  • Patent number: 12102670
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: October 1, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • Patent number: 12065477
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: August 20, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Heiko Schuster, Janet Peper, Kevin Roehle, Philipp Wagner, Hans-Georg Rammensee
  • Patent number: 12053504
    Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: August 6, 2024
    Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLC
    Inventor: Xiaodong Feng
  • Patent number: 12016935
    Abstract: Among the various aspects of the present disclosure is the provision of compositions of imaging agents and methods for use in detecting, monitoring, and evaluating CCR2 associated diseases, disorders, and conditions.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: June 25, 2024
    Assignee: Washington University
    Inventors: Yongjian Liu, Robert Gropler, Steven Brody, Daniel Kreisel
  • Patent number: 12012462
    Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: June 18, 2024
    Assignee: Amgen Inc.
    Inventors: Michael John Giffin, Melissa Thomas, Christopher Murawsky, Ryan B. Case, Lawren Wu, Jed J. Wiltzius, Ruben Alvarez Rodriguez, Jun Feng
  • Patent number: 11998609
    Abstract: Disclosed are therapeutic self-assembling molecules including a peptide sequence conjugated to one or more antiviral therapeutics to form a peptide-based antiviral prodrug capable of self-assembly into supramolecular structures with varying morphology in aqueous solutions, which can be injected subcutaneously or intramuscularly for the long-acting treatment of chronic viral infections.
    Type: Grant
    Filed: November 7, 2022
    Date of Patent: June 4, 2024
    Assignee: The Johns Hopkins University
    Inventors: Honggang Cui, Charles Williams Flexner, Maya Monroe, Han Wang
  • Patent number: 11981731
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: May 14, 2024
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • Patent number: 11965041
    Abstract: The present invention provides N-methylated cyclic hexapeptides comprising RGD and at least one alanine residue. The present invention further provides prodrugs comprising the cyclic hexapeptides. Pharmaceutical compositions comprising said cyclic hexapeptides are also disclosed as well as methods of their production and use in treating integrin related conditions and diseases.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: April 23, 2024
    Assignee: TECHNISCHE UNIVERSITAET MUENCHEN
    Inventors: Horst Otto Kessler, Chaim Gilon, Amnon Hoffman, Michael Weinmuller, Florian Rechenmacher, Joseph Fanous, Adi Klinger
  • Patent number: 11918607
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: March 5, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Patent number: 11897925
    Abstract: Disclosed are compounds, compositions, uses and methods using inhibitors of the CIP2A-TOPBP1 complex or agents that inhibit phosphopeptide recognition of TOPBP1 BRCT7/8, for treatment of a cancer associated with or characterized by a homologous recombination (HR) deficiency or treatment of cancer cells having HR deficiency.
    Type: Grant
    Filed: November 6, 2021
    Date of Patent: February 13, 2024
    Assignee: Sinai Health System
    Inventors: Daniel Durocher, Salomé Adam, Silvia Emma Rossi, Yibo Xue
  • Patent number: 11885796
    Abstract: An in vitro method for identifying an anti-cancer agent, the therapeutic efficacy of which is enhanced upon administration with a second agent that increases the expression of OPRK1 and/or BAD, comprising the steps of: a. co-incubating a population of cells with a target anti-cancer agent and said second agent and b. measuring the cytotoxicity and/or cytostasis in the population of cells; wherein the therapeutic efficacy of the target anti-cancer agent is enhanced if the cytotoxicity and/or cytostasis of the target anti-cancer agent is increased compared to a control.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: January 30, 2024
    Assignee: LDN Pharma Ltd.
    Inventors: Angus Dalgleish, Wai Lui
  • Patent number: 11859088
    Abstract: A color material aqueous solution having excellent thermal stability under acidic conditions, a method for manufacturing such a color material aqueous solution, and a blue-colored beverage are provided. Provided are: an acidic color material aqueous solution containing phycocyanin (A), a polyvalent carboxylic acid (B) containing one or more hydroxy groups, and at least one kind of nonionic emulsifier (C) selected from the group consisting of sucrose esters and polyglycerol esters, the at least one kind of nonionic emulsifier (C) having an HLB of 15 or more; a method for manufacturing an acidic color material aqueous solution including a step of dissolution in water (D); a method for manufacturing a color material aqueous solution in which the raw materials are dissolved in water; and a blue-colored beverage.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: January 2, 2024
    Assignee: DIC Corporation
    Inventors: Hiromasa Nakamura, Hisayoshi Arai
  • Patent number: 11845795
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 19, 2023
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • Patent number: 11833194
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: December 5, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11820837
    Abstract: The present disclosure relates to a modified peptide including (i) an amino acid sequence (X)-GRT-(Y)-TLC-(Z), or (ii) an amino acid sequence having at least 40% sequence identity to the amino acid sequence (X)-GRT-(Y)-TLC-(Z), wherein X, Y, and Z are the same as described in the specification. In this regard, methods for inhibiting the activity of at least one enzyme selected from the group consisting of AKT1 (PKB alpha), AKT2 (PKB beta), MAP3K8 (COT), MST4, AURKB (Aurora B), ROCK1, RPS6KB1 (p70S6K), CDC42 BPA (MRCKA), BRAF, RAF1 (cRAF) Y340D Y341D, SGK (SGK1), MAP4K4 (HGK), AURKA (Aurora A), AURKC (Aurora C), BRAF V599E, CHEK1 (CHK1), GSG2 (Haspin), CHEK2 (CHK2), FGR, IKBKB (IKK beta), CDK7/cyclin H/MNAT1, and CDC42 BPB (MRCKB) and Abl; and inhibiting cell proliferation are also provided, as are methods for preventing or treating cancer or a neurodegenerative disease or disorder.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: November 21, 2023
    Assignee: Advanced Technologies for Novel Therapeutics, LLC
    Inventor: Effat S. Emamian
  • Patent number: 11780898
    Abstract: Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition of IL-11-mediated signalling.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 10, 2023
    Assignees: Singapore Health Services PTE LTD., National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer, Wei Wen Lim, Benjamin Wei Ming Ng
  • Patent number: 11781142
    Abstract: Aspects of the disclosure relate to methods and compositions for treating pancreatic cancer (e.g., islet cell tumors). In some aspects, adeno-associated virus (AAV) may be used to deliver an interfering RNA that targets thymidylate synthase (TS).
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: October 10, 2023
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Maria Zajac-Kaye, Kyungah Maeng
  • Patent number: 11723947
    Abstract: The invention relates to a peptide comprising the amino acid sequence LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRP, wherein the amino acids in said amino acid sequence are D-amino acid residues, and to methods for the use of this peptide in the treatment of age-related disorders.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: August 15, 2023
    Assignee: Erasmus University Medical Center Rotterdam
    Inventor: Peterus Leonardus Josephus de Keizer
  • Patent number: 11709165
    Abstract: [Object] To provide a novel examination method for a cancer treatment effect, screening method for a peptide for a cancer vaccine, and peptide and composition for inducing an immune response against cancer. [Solving Means] Provided are an examination method for a cancer treatment effect and a screening method for a peptide for a cancer vaccine each including detecting an antibody against a cancer/testis antigen or an anti-p53 antibody in a sample. It is suitable that an anti-XAGE1 antibody (IgG and/or IgA) be detected, or an anti-NY-ESO-1 antibody (IgG) be detected. Also provided are a novel peptide and novel composition for inducing immune responses against cancer.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: July 25, 2023
    Assignee: KAWASAKI GAKUEN EDUCATIONAL FOUNDATION
    Inventors: Mikio Oka, Eiichi Nakayama, Yoshihiro Ohue, Koji Kurose
  • Patent number: 11672847
    Abstract: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: June 13, 2023
    Assignee: Stemline Therapeutics, Inc.
    Inventors: Ivan Bergstein, Christopher Brooks, Thomas P. Cirrito
  • Patent number: 11579147
    Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: February 14, 2023
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard, Centre Leon Bernard
    Inventors: Philippe Naquet, Franck Galland, Virginie Millet, Jean-Yves Blay, Caroline Giessner
  • Patent number: 11560422
    Abstract: Sulfonamide-containing linkage systems for release of payload compounds from an attached targeting moiety in drug conjugates. The conjugates have the formula of [(P)-(L)]m-(T), wherein (P) is a payload compound, (L) is a linker, (T) is a targeting moiety and m is an integer from 1- to 10. Also provided are pharmaceutical compositions comprising such conjugates and there use in treating cancer.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: January 24, 2023
    Inventors: Geoffrey C. Winters, Alexander L. Mandel, Elyse Marie Josée Bourque, James R. Rich, Tom Han Hsiao Hsieh
  • Patent number: 11548935
    Abstract: Polypeptides derived from fibronectin are presented that are neutrophil elastase-resistant and can bind to growth factors and/or enhance growth factor activity. These polypeptides are useful for enhancing wound healing in a patient.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: January 10, 2023
    Assignee: NeoMatrix Therapeutics Inc.
    Inventors: Richard August Clark, Fubao Lin
  • Patent number: 11505579
    Abstract: The present invention relates to methods of treating a disease characterised by aberrant cell proliferation (e.g., a cancer) in a human subject in need thereof. In particular, the present invention relates to treating the above conditions by administering a therapeutically effective amount of at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon, and administering to the subject at least one agent that inhibits the Hedgehog (Hh) signalling pathway (e.g., Vismodegib). Also provided are pharmaceutical compositions, including controlled release pharmaceutical compositions, containing at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon (e.g., a checkpoint inhibitor), an inhibitor of Hh signalling pathway, and a controlled release matrix such as a SiO2 matrix gel.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: November 22, 2022
    Assignee: ASCEND BIOPHARMACEUTICALS, INC.
    Inventors: Clement Leong, Geoffrey Pietersz
  • Patent number: 11497740
    Abstract: Disclosed are methods for the use of Jumonji C demethylase inhibitors for the radiosensitization of cancers cells and the treatment and prevention of chemotherapy resistance in cancer.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 15, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maithili P Dalvi, Elisabeth D Martínez, John D Minna, Juan Bayo-Fina, Amit Das
  • Patent number: 11498948
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: November 15, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 11485765
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: November 1, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11479807
    Abstract: The present technology relates generally to methods and compositions for targeted nucleic acid sequence enrichment, as well as uses of such enrichment for error-corrected nucleic acid sequencing applications. In some embodiments, highly accurate, error corrected and massively parallel sequencing of nucleic acid material is possible using a combination of uniquely labeled strands in a double-stranded nucleic acid complex in such a way that each strand can be informatically related to its complementary strand, but also distinguished from it following sequencing of each strand or an amplified product derived therefrom. In various embodiments, this information can be used for the purpose of error correction of the determined sequence.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 25, 2022
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Scott R. Kennedy, Jesse J. Salk, Michael Hipp, Elizabeth Schmidt, Rosa Ana Risques, Daniela Nachmanson
  • Patent number: 11466072
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: October 11, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 11458127
    Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: October 4, 2022
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Joshua Murtie, Nelamangala Nagaraja, Brandon Nicolay, David Schenkein, Katharine Yen
  • Patent number: 11459394
    Abstract: The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: October 4, 2022
    Assignee: MACROGENICS, INC.
    Inventors: Liqin Liu, Chia-Ying Kao Lam, Gundo Diedrich, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini
  • Patent number: 11446321
    Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: September 20, 2022
    Assignee: Leukos Biotech, S.L.
    Inventors: Ruth Muñoz Risueño, Mari Carmen Lara Castillo, Amaia Etxabe Alberdi
  • Patent number: 11447539
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: September 20, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 11440958
    Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 13, 2022
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Yi Tian Png, Natasha Vinanica, Takahiro Kamiya, Dario Campana
  • Patent number: 11433098
    Abstract: The invention relates to immunotherapeutic treatment of cancer. In particular, the invention relates to methods of treating cancer carrying a histone H3K27M (H3K27M) mutation (e.g., diffuse midline glioma with H3K27M mutation) using immunotherapeutic compositions comprising immune cells engineered to express GD2-specific chimeric antigen receptors.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: September 6, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michelle Monje-Deisseroth, Robbie Majzner, Crystal Mackall, Christopher Mount
  • Patent number: 11427932
    Abstract: This document relates to materials and methods for the production of protein. In one aspect, this document provides a nucleic acid construct including a first alcohol oxidase promoter element, wherein the first alcohol oxidase promoter element includes a mutation at one or more nucleotide positions corresponding to any of nucleotide positions 668-734 relative to SEQ ID NO: 28.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 30, 2022
    Assignee: Impossible Foods Inc.
    Inventors: Martin Andrew Hoyt, Xiao Guo, Smita Shankar
  • Patent number: 11414458
    Abstract: The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: August 16, 2022
    Assignees: Agenus Inc., The Board of Regents of the University of Oklahoma
    Inventors: Donald F. Hunt, Andrew Norris, Ann Michelle English, Jeffrey Shabanowitz, William H. Hilderbrand, Oriana E. Hawkins
  • Patent number: 11400138
    Abstract: A method for improving a skin condition of a subject in need thereof includes administering to the subject a composition including a bioactive compound. The bioactive compound is a peptide, and includes at least one amino acid sequence as set forth in SEQ ID NO: 1 to SEQ ID NO: 11. Each of the amino acid sequence is a peptide of fish skin.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: August 2, 2022
    Assignee: TCI CO., LTD.
    Inventors: Yung-Hsiang Lin, Yu-Ling Wang
  • Patent number: 11382905
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: July 12, 2022
    Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
  • Patent number: 11339209
    Abstract: The invention provides novel compositions, methods, and therapeutic uses related to fusogenic protein MINION (microprotein inducer of fusion).
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: May 24, 2022
    Assignee: NOVARTIS AG
    Inventors: Stephane Corbel, Srihari Cidambi Sampath, Srinath Cidambi Sampath, Christian Schmedt, Qiao Zhang
  • Patent number: 11338027
    Abstract: The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 24, 2022
    Assignee: AMAL THERAPEUTICS SA
    Inventors: Madiha Derouazi, Elodie Belnoue
  • Patent number: 11340235
    Abstract: The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterized by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilization of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a system and kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD), primary sclerosing cholangitis (PSC), and/or ulcerative colitis (UC).
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 24, 2022
    Assignee: GA GENERIC ASSAYS GMBH
    Inventor: Dirk Roggenbuck
  • Patent number: 11326202
    Abstract: The present invention provides methods, compositions and kits for enriching and determining nucleotide sequences of a plurality of target loci from a sample comprising nucleic acids. The methods comprise one or more cycles of primer extension followed by PCR amplification of target sequences using nested target-specific primers.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: May 10, 2022
    Assignee: HELITEC LIMITED
    Inventor: Zongli Zheng
  • Patent number: 11285220
    Abstract: The present invention relates to protein drug conjugates, methods of manufacturing the same and their use in therapy. In particular, the present invention relates to protein drug conjugates comprising a globular protein, an improved linker and a drug for use in targeted drug delivery applications.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: March 29, 2022
    Assignee: Iksuda Therapeutics Limited
    Inventors: Anthony David Baxter, Christopher Michael Birchall, David James Mansell, Justyna Helena Mysliwy, Jenny Thirlway
  • Patent number: 11253568
    Abstract: Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin V to the subject.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 22, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Francis G. Blankenberg
  • Patent number: 11248252
    Abstract: Disclosed are composition and methods for treating immune disorders. Also disclosed are diagnosis methods and prognosis methods.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 15, 2022
    Inventors: Zhenglun Zhu, Hong Gao
  • Patent number: 11242375
    Abstract: Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (CAR), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the CAR binds to a cancer antigen. Also disclosed herein are T cells that recognize and are sensitized to a cancer antigen, which T cells recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response. Additionally provided are methods of using such cells to treat cancer in a subject in need thereof.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: February 8, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Prasad S. Adusumilli, Michel Sadelain
  • Patent number: 11229711
    Abstract: Provided herein are antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: January 25, 2022
    Assignee: Magenta Therapeutics, Inc.
    Inventors: David Y. Jackson, Edward Ha
  • Patent number: 11229679
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: January 25, 2022
    Assignee: ANCHORED RSK3 INHIBITORS, LLC
    Inventors: Michael S. Kapiloff, Jinliang Li, Michael Kritzer